Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

DARMSTADT, Germany — (BUSINESS WIRE) — Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and se…